Sign in Subscribe

targeted-therapy

A collection of 104 issues

Collision tumor case reveals dual primary colorectal cancers with distinct molecular profiles

Skip to content The CRC Digest ◇ RESEARCH Collision tumor case reveals dual primary colorectal cancers with distinct molecular profiles Researchers report a rare collision tumor composed of two adjacent primary colorectal carcinomas, one harboring a TPR::NTRK fusion with MSI-H and high tumor mutational burden, the other showing conventional adenocarcinoma

Encorafenib, cetuximab, and nivolumab rechallenge succeeds in BRAF V600E mCRC case

Skip to content The CRC Digest Encorafenib, cetuximab, and nivolumab rechallenge succeeds in BRAF V600E mCRC case A case report from the AGMT mCRC Registry describes successful rechallenge with encorafenib and cetuximab combined with nivolumab in a patient with BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer. (Clinical Colorectal Cancer) This

ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC

Skip to content The CRC Digest ▸ TREATMENT ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC A Phase II trial enrolled patients with RAS/BRAF wild-type metastatic colorectal cancer who had progressed on prior cetuximab-based therapy, using circulating tumor DNA testing to select patients for rechallenge

Fruquintinib plus immunotherapy evaluated in MSS refractory mCRC

Skip to content The CRC Digest Fruquintinib plus immunotherapy evaluated in MSS refractory mCRC A retrospective study of 145 patients with microsatellite-stable metastatic CRC who had progressed after at least two systemic treatment lines aimed to evaluate whether fruquintinib alone, fruquintinib plus a PD-1 inhibitor, or the combination with radiotherapy

Meta-analysis finds conflicting evidence on ctDNA RAS testing for anti-EGFR therapy

Skip to content The CRC Digest ◇ RESEARCH Meta-analysis finds conflicting evidence on ctDNA RAS testing for anti-EGFR therapy A systematic review of patients with tissue RAS wild-type tumors receiving first-line chemotherapy plus anti-EGFR therapy found inconsistent results on whether ctDNA RAS status predicts outcomes, possibly due to differences in assay

Calcitriol Modulates Age-Dependent Drug Response in Patient-Derived Colorectal Organoids

Skip to content The CRC Digest Calcitriol Modulates Age-Dependent Drug Response in Patient-Derived Colorectal Organoids Researchers used paired patient-derived normal and tumor colorectal organoids to investigate how calcitriol (the active vitamin D metabolite) modulates chemotherapy response. Dose-response analyses revealed marked interpatient variability, with SN38 being more potent than 5-fluorouracil and

Dual Oral Regimen Shows Activity in KRAS G12C–Mutated Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Dual Oral Regimen Shows Activity in KRAS G12C–Mutated Metastatic CRC A phase Ib/II trial evaluated the chemotherapy-free combination of ifebemtinib (a FAK inhibitor) plus garsorasib (a KRAS G12C inhibitor) in previously treated KRAS G12C–mutated metastatic colorectal cancer, showing encouraging antitumor

HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer

Skip to content The CRC Digest HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer A case report describes a significant response in a 54-year-old male with HER2-amplified, KRAS G12D-mutated metastatic rectal cancer treated with a zanidatamab-based combination regimen. (Frontiers in Immunology) This content is informational only and does not constitute

Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC A population-based multicenter study examined real-world outcomes of the targeted therapy combination encorafenib plus panitumumab in patients with BRAF V600E-mutated metastatic colorectal cancer. (Clinical Colorectal Cancer) This content is informational only and

Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer While approved KRAS therapies target only the rare G12C mutation, new drugs including MRTX1133, zoldonrasib, and daraxonrasib are being developed to directly target G12D and G12V—the most common